EUVIMEDEUVIMED entdecken
Crossref

Design and Synthesis of KRAS G12C Inhibitors for Antitumor Evaluation Harboring Combination Therapy with Nrf2, PARP-7, and Pan-USP Inhibitors to Alleviate Drug Resistance Synergistically

Liangliang Tian, Qingxuan Han, Yanlong Qiao, Peng Chu, Lixue Chen iD

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.5c02703 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Liangliang Tian und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Dalian Medical University, Dalian 116044, P.R. China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Antineoplastic Agents, Drug Design, NF-E2-Related Factor 2. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Technology Star Program of Dalian City, Scientific Research Fund of Liaoning Province Education Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Compared with positive control MRTX849, the synthesized compounds 7g, 7p, 7q, 7r, 7v, and 7y displayed stronger antiproliferative activities against H358 cells with IC50 values of < 1 nM (3D cell culture) and comparable inhibitory potency against KRASG12C. Among them, 7q (MH5) exhibited satisfactory cellular selectivity, moderate pharmacokinetic characters, and good anticancer effects on pancreatic, colorectal cancer xenograft in vivo. Meaningfully, 7q combined with Nrf2 inhibitor ML385 or PARP7 inhibitor RBN-2397 greatly enhanced the sensitivity of 7q against lung cells (H1373) in vivo. Furthermore, combination therapy of 7q with pan-USP inhibitor PR-619 obtained a statistically significant synergistic inhibition of H1373 cell growth in vitro and in vivo. Our findings indicate that 7q may be a promising drug candidate for the treatment of cancers harboring the KRASG12C mutation, and the results of the combination regimen established a pharmacological foundation for addressing drug resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmAntineoplastic AgentsDrug DesignNF-E2-Related Factor 2Proto-Oncogene Proteins p21(ras)Poly(ADP-ribose) Polymerase InhibitorsHumansAnimalsCell Line, TumorMiceDrug SynergismCell ProliferationMice, NudeStructure-Activity RelationshipXenograft Model Antitumor Assays

Substanzen

Antineoplastic AgentsNF-E2-Related Factor 2Proto-Oncogene Proteins p21(ras)KRAS protein, humanPoly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • College of Pharmacy, Dalian Medical University, Dalian 116044, P.R. China.
  • School of Science, Westlake University, Hangzhou 310030, P.R. China.

ORCID-Profile: Lixue Chen

Förderung

  • Technology Star Program of Dalian City
  • Scientific Research Fund of Liaoning Province Education Administration

Zitieren

APA

Tian, L., Han, Q., Qiao, Y., Chu, P., & Chen, L. (2026). Design and Synthesis of KRAS G12C Inhibitors for Antitumor Evaluation Harboring Combination Therapy with Nrf2, PARP-7, and Pan-USP Inhibitors to Alleviate Drug Resistance Synergistically. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02703

Vancouver

Tian L, Han Q, Qiao Y, Chu P, Chen L. Design and Synthesis of KRAS G12C Inhibitors for Antitumor Evaluation Harboring Combination Therapy with Nrf2, PARP-7, and Pan-USP Inhibitors to Alleviate Drug Resistance Synergistically. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c02703

BibTeX
@article{Tian2026,
  author = {Tian, Liangliang and Han, Qingxuan and Qiao, Yanlong and Chu, Peng and Chen, Lixue},
  title = {Design and Synthesis of KRAS G12C Inhibitors for Antitumor Evaluation Harboring Combination Therapy with Nrf2, PARP-7, and Pan-USP Inhibitors to Alleviate Drug Resistance Synergistically},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.5c02703}
}
Kostenlos starten →